2021年4月19日

ImpriMed -兽医精密医学领先的创业公司最近宣布,它已经关闭了总共800万美元的项目前期融资。这些都是细节。ImpriMed -兽医精密医学领先的创业公司最近宣布,它已经关闭了总共800万美元的项目前期融资770万美元的风险投资和其他政府拨款。这一轮的资金是由HG倡议和其他参与者包括Draper Associates德雷伯龙,BonAngels,骨螺伙伴,Translink投资,底漆Sazze, FuturePlay, ES投资者。ImpriMed做什么工作?ImpriMed利用人工智能来预测哪些抗癌药物最有可能是有效的为特定的狗的淋巴瘤或白血病使用实时数据生成的化学敏感性和immunophenotyping化验病人的新鲜的癌细胞。和创新的方法,使宠物癌症治疗的兽医肿瘤学家化疗决策与信心,知道量化预测在实际药物管理局药物反应。这轮融资,ImpriMed计划开发额外的预测模型对他们当前的目标病人犬血液癌症,扩大他们的客户网络,扩大管道在狗和猫其他类型的癌症。ImpriMed已经能够临床验证与同行评审的期刊出版的专利技术在兽医和比较肿瘤证明一个准确的预测减少肿瘤大小和更快的时间缓解当使用ImpriMed化疗反应预测服务。到目前为止,超过2000服务已经提供给社区治疗犬的病人。 KEY QUOTES: “ImpriMed is breaking new ground in medicine. Using artificial intelligence to test drugs in pets can lead to solving many diseases in pets and the company could be an onramp for breakthroughs with humans. Enormous opportunity.” — Tim Draper, Founding Partner at Draper Associates “HG Initiative along with other investors, is a welcome endorsement for ImpriMed’s AI-Driven Personalized Chemo Response Prediction tool and its viability. We look forward to all the benefits and access this funding will provide to support oncologists and pet parents to improve therapeutic options for their pets and will allow us to develop more finely tuned AI models to increase the accuracy of our service reports.” — Dr. Sungwon Lim, CEO and Co-Founder at ImpriMed